International journal of dermatology
June 28, 2026 · via Europe PMC
Efficacy of Intralesional Bevacizumab Versus Intralesional Triamcinolone Acetonide Injection in the Treatment of Keloids: A Randomized Clinical Trial.
Hilal RF, Osama N, El-Tahlawi S, Elbendary A, Nour ZA, Ragab N.
AI summary — for doctors, generated from the abstract only
Intralesional triamcinolone outperformed intralesional bevacizumab for post-traumatic keloids in a small randomized trial.
What was studied
Randomized trial of 28 adults with post-traumatic keloids given monthly intralesional triamcinolone or bevacizumab for three sessions, assessed by modified Vancouver Scar Scale, erythema, histology and biochemical markers.
Key findings
- The mVSS difference significantly favored triamcinolone (exact values not in the abstract).
- Triamcinolone lowered VEGF and raised collagen type III, while bevacizumab improved collagen fibre spacing.
- Patient satisfaction and physician global assessment favored triamcinolone.
Clinical relevance
Triamcinolone remains the more effective option of the two, with bevacizumab possibly worth studying for early or vascular keloids or as an adjuvant.
Who should care
Limitations
Only 28 patients, short follow-up, and the abstract gives no effect sizes, recurrence rates or safety numbers.
Triamcinolone did better in this small trial.
This is an AI-generated summary of the published abstract, not a clinical recommendation. It may not reflect the full text or subsequent updates — verify against the original source before acting on it.
Abstract
Background
Keloids are an abnormal fibroproliferative disorder that often causes pruritus, pain, and hyperpigmentation, thereby significantly impacting quality of life. Vascular endothelial growth factor (VEGF) is upregulated in scars and, therefore, can be a potential target for their treatment.
Objectives
Our aim was to evaluate the efficacy and safety of intralesional triamcinolone acetonide (TAC) versus intralesional bevacizumab injection in the treatment of post-traumatic keloids.
Methods
This randomized clinical trial was conducted on 28 adult patients with post-traumatic keloids. Patients were randomized into two groups; one group received intralesional triamcinolone acetonide, and the other received intralesional bevacizumab. Injections were done monthly. Patients received a total of three sessions. Therapeutic efficacy was defined in terms of the modified Vancouver Scar Scale (mVSS), erythema index by spectrophotometry, histopathological evaluation, and biochemical assessment of VEGF, collagen type I, and collagen type III levels.
Results
A statistically significant difference in mVSS was observed between the triamcinolone acetonide and bevacizumab groups, favoring the TAC group. The TAC group showed a significant decrease in VEGF level and an increase in collagen type III after treatment. The bevacizumab group showed significant improvement in the spacing between collagen fibers after treatment. The patient satisfaction score and the physician global assessment revealed superior outcomes regarding intralesional triamcinolone acetonide.
Conclusion
Despite the superior results observed with triamcinolone, bevacizumab warrants further investigation to determine whether it can be used for early and vascular keloids or as an adjuvant to optimize results.
Trial registration
ClinicalTrials.gov identifier: NCT07014280.
DOI
10.1111/ijd.70548
PMID
42365524
Research metadata (titles, abstracts, authors, publication dates) is sourced from Europe PMC, which aggregates content from PubMed/MEDLINE, PubMed Central, and other providers under the U.S. National Library of Medicine (NLM/NCBI). NLM does not claim copyright on abstracts; the original journal publishers or authors may hold rights to the full articles. AI-generated summaries are derived only from the abstract, never the full text, and are always labeled as AI-generated.
Want more like this?
Browse more from the feed. A free account unlocks the full feed, saving and communities.
Back to the research feed